Community triage for lower limb vascular concerns: reducing the burden on hospitals QP Case Study October 2016
Medicines optimisation peer review: improving prescribing and lowering costs QP Case Study September 2016 Very High
Medicines management assistants: to reduce medicine wastage QP Case Study August 2016 Very High
Continuous passive motion following total knee arthroplasty in people with arthritis Cochrane Topic August 2016 Unclassified
Improving the quality of care for men with lower urinary tract symptoms: shared decision making QP Case Study July 2016 High
Improving diagnosis and quality of care for people with IBS across Somerset QP Case Study July 2016 High
Topotecan is not recommended within its marketing authorisation for treating recurrent platinum-resistant or platinum-refractory ovarian cancer. Do not do June 2016
Chlamydia screening should not be offered as part of routine antenatal care. Do not do June 2016
The following are not recommended within their marketing authorisations for treating the first recurrence of platinum-sensitive ovarian cancer: •gemcitabine in combination with carboplatin •trabectedin in combination with PLDH •topotecan. The appraisal committee was unable to make recommendations on the use of these technologies for treating platinum-sensitive ovarian cancer beyond the first recurrence. Do not do June 2016
Although there is a great deal of material published on alternative screening methods for pre-eclampsia, none of these has satisfactory sensitivity and specificity, and therefore they are not recommended. Do not do June 2016